甲磺酸伊马替尼在慢性髓样白血病患者中引起Sweet综合征1例

• 作 者: Ayirookuzhi S.J. Ramshesh P. Mills G. 罗素菊 冯义国
• 机 构: LA State Univ. Hlth. Sciences Center 1501 Kings Highway Shreveport LA 71130 United States Dr. ,
• 出 处: 世界核心医学期刊文摘(皮肤病学分册)
• 发表日期: 2005年07期
• 关键词: 甲磺酸伊马替尼 白血病 综合征 嗜中性 皮肤反应 美国女性 化疗药 甲磺酸盐 继发 Sweet

Background: Imatinib mesylate has become one of the main chemotherapeutic agents currently used to treat patients with chronic myeloid leukemia (CML). Although cutaneous reactions to this drug have been documented before, this is the first time that Sweet syndrome has been reported with its use. Observations: We report a case of Sweet syndrome secondary to the administration of imatinib to treat CML. On 2 separate occasions, a 53-year-old African American woman with CML developed neutrophilic dermatosis consistent with Sweet syndrome after chemotherapy with imatinib. Conclusion: Greater awareness of the adverse effects of imatinib and the character- ization of its cutaneous adverse effects will lead to improved surveillance for and treatment of those adverse effects.

Background: Imatinib mesylate has become one of the main chemotherapeutic agents currently used to treat patients with chronic myeloid leukemia (CML). Although cutaneous reactions to this drug have been documented before, this is the first time that Sweet syndrome has been reported with its use . Observations: We report a case of Sweet syndrome secondary to the administration of imatinib to treat CML. On 2 separate occasions, a 53-year-old African American woman with CML developed neutrophilic dermatosis consistent with Sweet syndrome after chemotherapy with imatinib. Conclusion: Greater awareness of the adverse effects of imatinib and the character-ization of its cutaneous adverse effects will lead to improved surveillance for and treatment of those adverse effects.